Table 3.

Binding potentials of [¹¹C]WIN-35,428 in the caudate nucleus and putamen of control subjects, abstinent methamphetamine users, abstinent methcathinone users, and Parkinson’s disease patients

	n	Caudate nucleus (k3/k4)	Putamen (k3/k4)
Control	10	7.5  ± 1.7  (8.7 ± 1.6)	7.3  ± 1.4  (8.3 ± 1.4)
Methamphetamine	6	5.8  ± 1.0*  (7.0 ± 1.2)*	5.5  ± 0.9*  (6.7 ± 0.9)*
Methcathinone	4	5.7  ± 0.9*  (6.7 ± 1.3)*	6.1  ± 0.4*  (7.1 ± 0.6)
Parkinson’s disease	3	4.0  ± 0.9*  (5.4 ± 1.2)*	2.3  ± 0.4**  (3.1 ± 0.6)**

k₃/k₄ or binding potential (BP) values were determined using a three-compartment model and represent caudate nucleus bound/free and putamen bound/free [¹¹C]WIN-35,428, respectively. The age adjustment was made using PET imaging data from van Dyck et al. (1995) suggesting that DAT density in the human striatum declines with age at the rate of 0.8%/year, assuming no decline during the first 10 years of life. BP values were corrected for age using the following equation: [(age − 10 in years) × 0.8% DAT decline per year + 100] × [uncorrected BP value], recognizing that the 0.8%/year estimate of DAT decline may be somewhat high (Tedroff et al., 1988; Volkow et al., 1994). Values shown are the mean ± SD. n = Number of subjects. *Designates significant difference from control group; **designates significant difference from all other groups. Values in parentheses represent BP values corrected for age.